Diversity in Clinical Trials: The Need to Take Action
Gadi Saarony, CEO of Advarra discusses the current state of diversity in clinical trials and how industry needs to be more proactive in addressing it.
Gadi Saarony, CEO of Advarra examines the current state of diversity in clinical research. He discusses the need for industry to take more action in making trials more diverse, what regulatory bodies need to do to increase awareness, and how researchers can best reach diverse populations.
About the speaker
Gadi Saarony, CEO of Advarra has over 25 years of leadership experience, including commercial and operational clinical research roles. Prior to joining Advarra, he served as Executive Vice President and Chief Clinical Research Services Officer at Parexel where he was responsible for operational delivery of company research services such as patient recruitment and data management.
About the ACT Podcast
The editors of Applied Clinical Trials bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on Spotify and Google Podcasts
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
